Advertisement
U.S. markets open in 9 hours 7 minutes

Alkermes plc (ALKS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
27.53-1.22 (-4.24%)
At close: 04:00PM EDT
27.53 0.00 (0.00%)
After hours: 05:39PM EDT

Alkermes plc

Connaught House
1 Burlington Road Dublin 4
Dublin D04 C5Y6
Ireland
353 1 772 8000
https://www.alkermes.com

Sector(s)Healthcare
IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees2,100

Key Executives

NameTitlePayExercisedYear Born
Mr. Richard F. PopsChairman & CEO2.3M5.15M1962
Mr. Blair C. JacksonInterim Principal Financial Officer, Executive VP & COO1.05M652.85k1973
Mr. David Joseph GaffinExecutive VP, Chief Legal Officer, Chief Compliance Officer & Secretary1.08MN/A1972
Mr. Iain Michael BrownSenior VP & CFO (Leave of Absence)867.75kN/A1969
Dr. Craig C. Hopkinson M.D.Executive VP of Research & Development and Chief Medical Officer1.12MN/A1968
Dr. Floyd E. Bloom M.D.Founder57.73kN/A1937
Mr. Samuel J. ParisiInterim Principal Accounting Officer & VP of FinanceN/AN/A1975
Mr. Thomas HarveyChief Information Officer & Senior VP of ITN/AN/AN/A
Ms. Sandra CoombsSenior Vice President of Corporate Affairs & Investor RelationsN/AN/AN/A
Mr. Michael J. LandineSenior VP of Corporate Development & Chief Risk Officer750.46k234.46k1954
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Corporate Governance

Alkermes plc’s ISS Governance QualityScore as of March 1, 2024 is 3. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 3; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.